Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Shalby IPO subscribed...

    Shalby IPO subscribed 46 percent as on Day 2

    Written by Ruby Khatun Khatun Published On 2017-12-07T10:45:08+05:30  |  Updated On 7 Dec 2017 10:45 AM IST
    Shalby IPO subscribed 46 percent as on Day 2

    New Delhi: The initial public offer of Shalby Ltd, the Ahmedabad-based multi-specialty hospital chain, was subscribed 46 per cent as on the second day of the bidding.


    The IPO, which aims to raise Rs 504 crore, received bids for over 66 lakh shares as against the total issue size of 1.45 crore -- a subscription of 46 percent -- data available with the National Stock Exchange (NSE) showed.


    The initial share sale, which opened for public subscription on Tuesday, will close today. Shalby on Monday raised over Rs 150 crore from anchor investors.


    The IPO comprises a fresh issue of shares aggregating up to Rs 480 crore and an offer for sale of up to 10 lakh equities.

    The price band has been fixed at Rs 245-248. At the upper end, the public issue would fetch Rs 504 crore.

    Proceeds of the IPO will be utilized towards repayment of borrowings by the company, besides the purchase of medical equipment for the existing, recently set-up as well as upcoming hospitals.

    In recent months, healthcare services firms Alkem Laboratories, Dr. Lal Pathlabs, Narayana Hrudayalaya, Thyrocare and Eris Lifesciences have tapped the primary market through the IPO route.

    46 percentAlkem LaboratoriesDay 2Dr Lal PathLabsEris Lifescienceshospitalsinitial public offeringIPOmedical equipmentmulti-specialty hospital chainNarayana HrudayalayaNational Stock ExchangeNSEshalbyShalby HospitalsShalby LtdsubscribedThyrocare
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok